Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative effectiveness of empirical antibiotic treatments in methicillin-susceptible Staphylococcus aureus infective endocarditis: A post hoc analysis of a prospective French cohort study.
Lecomte R, Deschanvres C, Bourreau A, Ruffier d'Epenoux L, Le Turnier P, Gaborit B, Chauveau M, Michel M, Le Tourneau T, Bémer P, Corvec S, Boutoille D. Lecomte R, et al. Among authors: chauveau m. Int J Infect Dis. 2024 May;142:106989. doi: 10.1016/j.ijid.2024.106989. Epub 2024 Feb 28. Int J Infect Dis. 2024. PMID: 38428479 Free article.
Characteristics and Prognosis Factors of Pneumocystis jirovecii Pneumonia According to Underlying Disease: A Retrospective Multicenter Study.
Lécuyer R, Issa N, Camou F, Lavergne RA, Gabriel F, Morio F, Canet E, Raffi F, Boutoille D, Cady A, Gousseff M, Crabol Y, Néel A, Tessoulin B, Gaborit B; PRONOCYSTIS Study Group. Lécuyer R, et al. Chest. 2024 Jan 11:S0012-3692(24)00022-9. doi: 10.1016/j.chest.2024.01.015. Online ahead of print. Chest. 2024. PMID: 38215935 Free article.
Effect of Swine Glyco-humanized Polyclonal Neutralizing Antibody on Survival and Respiratory Failure in Patients Hospitalized With Severe COVID-19: A Randomized, Placebo-Controlled Trial.
Gaborit B, Vanhove B, Lacombe K, Guimard T, Hocqueloux L, Perrier L, Dubee V, Ferre V, Bressollette C, Josien R, Thuaut AL, Vibet MA, Jobert A, Dailly E, Ader F, Brouard S, Duvaux O, Raffi F; POLYCOR study group. Gaborit B, et al. Open Forum Infect Dis. 2023 Oct 20;10(11):ofad525. doi: 10.1093/ofid/ofad525. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 37942459 Free PMC article.
Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study.
Hervochon C, Hennart B, Leroy AG, Corvec S, Boutoille D, Senneville É, Sotto A, Illes G, Chavanet P, Dubée V, Bleibtreu A, De Carné MC, Talarmin JP, Revest M, Castan B, Bellouard R, Dailly É, Allorge D, Dinh A, Le Turnier P, Gregoire M; Dalbavancin Pharmacokinetics (DALBAP) study group. Hervochon C, et al. J Antimicrob Chemother. 2023 Dec 1;78(12):2919-2925. doi: 10.1093/jac/dkad331. J Antimicrob Chemother. 2023. PMID: 37864551
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.
Bruel T, Vrignaud LL, Porrot F, Staropoli I, Planas D, Guivel-Benhassine F, Puech J, Prot M, Munier S, Bolland WH, Soulié C, Zafilaza K, Lusivika-Nzinga C, Meledge ML, Dorival C, Molino D, Péré H, Yordanov Y, Simon-Lorière E, Veyer D, Carrat F, Schwartz O, Marcelin AG, Martin-Blondel G; ANRS 0003S CoCoPrev Study Group. Bruel T, et al. Med. 2023 Oct 13;4(10):664-667. doi: 10.1016/j.medj.2023.07.007. Med. 2023. PMID: 37837962 Free article.
Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study.
Jaume L, Hau E, Monsel G, Mahé A, Bertolotti A, Petit A, Le B, Chauveau M, Duhamel E, Maisonobe T, Bagot M, Bouaziz JD, Mougari F, Cambau E, Jachiet M; Groupe d’infectiologie en dermatologie et des infections sexuellement transmissibles (GrIDIST). Jaume L, et al. Among authors: chauveau m. PLoS Negl Trop Dis. 2023 Apr 20;17(4):e0011238. doi: 10.1371/journal.pntd.0011238. eCollection 2023 Apr. PLoS Negl Trop Dis. 2023. PMID: 37079647 Free PMC article.
Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir.
Martin-Blondel G, Marcelin AG, Soulié C, Kaisaridi S, Lusivika-Nzinga C, Zafilaza K, Dorival C, Nailler L, Boston A, Ronchetti AM, Melenotte C, Cabié A, Choquet C, Trinh-Duc A, Lacombe K, Gaube G, Coustillères F, Pourcher V, Martellosio JP, Peiffer-Smadja N, Chauveau M, Housset P, Piroth L, Devaux M, Pialoux G, Martin A, Dubee V, Frey J, Le Bot A, Cazanave C, Petua P, Liblau R, Carrat F, Yordanov Y. Martin-Blondel G, et al. Among authors: chauveau m. Clin Microbiol Infect. 2023 Apr;29(4):543.e5-543.e9. doi: 10.1016/j.cmi.2022.12.016. Epub 2022 Dec 28. Clin Microbiol Infect. 2023. PMID: 36586513 Free PMC article.
Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2.
Martin-Blondel G, Marcelin AG, Soulié C, Kaisaridi S, Lusivika-Nzinga C, Dorival C, Nailler L, Boston A, Melenotte C, Cabié A, Choquet C, Coustillères F, Martellosio JP, Gaube G, Trinh-Duc A, Ronchetti AM, Pourcher V, Chauveau M, Lacombe K, Peiffer-Smadja N, Housset P, Perrot A, Pialoux G, Martin A, Dubee V, Devaux M, Frey J, Cazanave C, Liblau R, Carrat F, Yordanov Y. Martin-Blondel G, et al. Among authors: chauveau m. J Infect. 2022 Oct;85(4):e104-e108. doi: 10.1016/j.jinf.2022.06.033. Epub 2022 Jul 5. J Infect. 2022. PMID: 35803386 Free PMC article. No abstract available.
91 results